GeneDx (NASDAQ:WGS) Issues Earnings Results, Beats Estimates By $0.66 EPS

GeneDx (NASDAQ:WGS) posted its quarterly earnings data on Tuesday. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66, Zacks reports. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $111.31 on Thursday. The stock has a market capitalization of $3.06 billion, a PE ratio of -35.79 and a beta of 2.01. The business has a fifty day moving average price of $78.04 and a two-hundred day moving average price of $62.14. GeneDx has a fifty-two week low of $4.61 and a fifty-two week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. TD Cowen upped their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Wells Fargo & Company boosted their price target on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

Insider Buying and Selling

In other GeneDx news, CEO Katherine Stueland sold 51,420 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the completion of the sale, the chief executive officer now directly owns 1,720 shares in the company, valued at $162,505.60. This represents a 96.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction on Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the transaction, the chief financial officer now owns 28,200 shares in the company, valued at approximately $2,164,350. The trade was a 11.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 127,584 shares of company stock valued at $11,336,520 over the last quarter. 27.30% of the stock is owned by company insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.